PFE PFIZER INC

Price Chart

Executive Summary

RBC Capital double-upgraded Pfizer from Underperform to Sector Perform, maintaining a $25 price target, which sits roughly 3% below the current price of $25.70. The upgrade reflects a less bearish view, though the unchanged target indicates limited near-term upside conviction. Consensus is deeply mixed at 42% Buy, 50% Hold, and 8% Sell across 36 analysts, with a mean target of $29.19 offering 13.6% implied upside. The median target is $28, while the low is $24, placing RBC's target at the bottom quartile. RBC's historical accuracy is 55% on over 4,100 calls with a 2.7% average return — above average among covering firms but not top tier. Analyst activity over the past 30 days shows only this upgrade and no downgrades, while EPS revisions are roughly balanced (30-day: 7 up/7 down for the next quarter, 12 up/7 down for the fiscal year). No insider trades were reported, and short interest is elevated at a 55.4% ratio. The double-upgrade from a previously bearish firm is a modest positive signal, but the unchanged target and mixed cross-platform data temper conviction. For active traders, the call is a tactical neutral-to-slightly-positive signal rather than a strong directional catalyst.

Impact Score

Consensus & Targets

Among 36 analysts covering PFE, the breakdown is 6 Strong Buy, 9 Buy, 18 Hold, 2 Sell, and 1 Strong Sell. That translates to 42% Buy-ratings, 50% Hold, and 8% Sell. The consensus leans neutral with a notable bearish tail, reflecting ongoing uncertainty about Pfizer's growth drivers post-COVID.

The current price is $25.70. The mean price target is $29.19, median $28, high $36, and low $24. Implied upside to the mean is 13.6%. RBC's $25 target is below the mean and median, and just above the consensus low—placing it among the most bearish targets on the Street.

Recent Analyst Activity

Over the past 30 days, analyst activity shows 1 upgrade (RBC) and 0 downgrades. EPS revision trends are mixed: over the last 30 days, the next-quarter EPS saw 7 upward and 7 downward revisions, while the fiscal-year EPS had 12 up and 7 down. Estimates are roughly stable, with a slight positive tilt for longer horizons.

Firm Track Record — RBC Capital

RBC Capital accuracy: 55% on 4173 calls | avg return: 2.7%

Industry benchmark: mean 51% ± 11%. Top tier: ≥61% (mean + 1σ). Based on 7 firms with ≥5 scored calls.

RBC Capital has a 55% accuracy rate (2,282 correct calls out of 4,173 scored) with an average return of 2.7% on its rated stocks. This is above-average among firms covering PFE, where the top tier includes Morgan Stanley (71% on 7 calls) and BofA Securities (67% on 3 calls), while the weakest are Guggenheim (40%) and UBS (40%). RBC's accuracy is solid but not standout, so the double upgrade carries moderate weight.

Earnings Estimates

Cross-Platform Signals

No insider trades were recorded. Congressman Ro Khanna reported a small buy ($1K-$15K). Institutional activity is mixed: Norges Bank both initiated and exited large positions, Two Sigma more than doubled its stake (up 2,735%), Renaissance Technologies exited entirely, and Cullen Capital trimmed 38%. Short interest is elevated at 55.4% of volume, indicating significant bearish positioning. The lack of insider buying alongside an upgrade from a previously bearish firm creates a divergence; the high short interest could fuel a squeeze but also reflects persistent skepticism.

Documents Analyzed

Report based on filing metadata.

US Market Status